Afatinib Alone and Afatinib Plus Vinorelbine/Paclitaxel in Patients With HER2-Positive Breast Cancer With Prior Unsuccessful HER2-Targeted Therapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial
Breast Cancer Res Treat 2022 Feb 09;[EPub Ahead of Print], T Hickish, A Mehta, MC Liu, CS Huang, RS Arora, YC Chang, Y Yang, V Vladimirov, M Jain, J Tsang, K Pemberton, B Sadrolhefazi, X Jin, LM TsengFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.